A detailed history of Penserra Capital Management LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Penserra Capital Management LLC holds 1,274 shares of ALT stock, worth $11,466. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,274
Previous 882 44.44%
Holding current value
$11,466
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.5 - $8.1 $2,156 - $3,175
392 Added 44.44%
1,274 $7,000
Q2 2024

Aug 13, 2024

BUY
$5.91 - $10.23 $5,212 - $9,022
882 New
882 $6,000
Q4 2021

Feb 15, 2022

SELL
$8.69 - $12.48 $7,907 - $11,356
-910 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $295 - $588
35 Added 4.0%
910 $10,000
Q2 2021

Aug 12, 2021

BUY
$9.85 - $16.46 $295 - $493
30 Added 3.55%
875 $8,000
Q1 2021

May 13, 2021

BUY
$12.71 - $24.31 $1,080 - $2,066
85 Added 11.18%
845 $11,000
Q4 2020

Feb 12, 2021

BUY
$7.84 - $14.22 $5,958 - $10,807
760 New
760 $8,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $441M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Penserra Capital Management LLC Portfolio

Follow Penserra Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Penserra Capital Management LLC with notifications on news.